Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 69Triple Negative Breast Neoplasms 32Ovarian Neoplasms 21Neoplasm Metastasis 10Prostatic Neoplasms 8Pancreatic Neoplasms 7Fanconi Anemia, Complementation Group D1 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Advanced Breast Cancer 4Recurrence 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Inflammatory Breast Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms, Castration-Resistant 1Primary Myelofibrosis 1Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian 1

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian × olaparib × Breast × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡